CRISPR Lateral Flow Strip Procurement: Writing a Pilot-Batch Acceptance Plan

A useful CRISPR lateral flow strip pilot answers a purchasing question: can the specified strip, reporter and assay workflow meet agreed readout criteria before the order scales? Define the acceptance plan before testing, so a visually attractive result does not become the only basis for a bulk purchase.

This guide proposes an evaluation record for assay developers and procurement teams. It does not report experimental results or establish performance specifications for a particular assay.

1. Freeze the configuration being evaluated

Record the strip model and lot, reporter labels and sequence identifier, Cas system, reaction formulation, sample preparation method and dilution, strip running conditions, and observation time. Keep the current supplier instructions with the record. If a condition changes, identify the result as a separate configuration rather than pooling it with the original pilot.

The Due Bio Cas12/13 dedicated strip page describes a labeled-reporter readout component. The strip is not a complete pathogen-specific diagnostic test. Confirm reporter chemistry and signal interpretation for the exact model with the supplier before ordering evaluation material.

2. Agree on the controls and decision rules

Evaluation item What to define before the pilot What to record
Negative results Relevant negative samples, no-template controls and any process blanks required by the workflow Unexpected signals, invalid results and the conditions in which they occur
Positive results Appropriate positive reference material and concentrations relevant to the intended application Observed results across the predefined repeats and sample conditions
Validity The manufacturer’s control-line and validity rules for the exact strip format Valid and invalid counts, including repeat tests
Readout Observation window, illumination, reader method and handling of borderline results Images at the agreed time and individual reader decisions
Reproducibility Relevant operators, days and lots within the available pilot scope Results separated by operator, day, lot and configuration

Choose the number of repeats and acceptance thresholds according to the study objective and risk. A small feasibility pilot can identify workflow problems, but it cannot by itself establish clinical sensitivity, specificity, a detection limit or long-term stability.

3. Treat sample preparation as part of the system

If the proposed workflow includes a nucleic acid release reagent, record the sample matrix, treatment conditions and the amount of treated sample entering the downstream reaction. Evaluate the complete workflow under the intended conditions; performance with a purified reference sample does not establish performance with a crude clinical, veterinary or environmental matrix.

Keep strip-only investigations distinct from full-workflow comparisons. When assessing a changed release method, keep the other settings fixed where practicable and document any unavoidable changes. Discuss available sample preparation options through the Due Bio product catalogue, then confirm the current instructions and application-specific evaluation requirements.

4. Build a usable batch record

Retain lot identifiers, receipt and storage records, packaging condition, the version of each instruction, the run sheet and unedited result images. Record deviations and failed runs as well as successful ones. Ask which batch documents the supplier can provide, rather than assuming that every certificate or specification is included.

For a future lot comparison, preserve the agreed test procedure and suitable reference materials under their specified conditions. Define how a change in strip, reporter, buffer or packaging will be reviewed. Do not infer shelf life from a short incoming-inspection exercise.

5. Separate technical acceptance from commercial acceptance

The technical record should identify the evaluated configuration, deviations, unresolved questions and the decision to proceed, repeat or stop. The purchase record should separately confirm quantity, packaging, lead time, shipping terms and the agreed documents. Neither record substitutes for validation or any regulatory obligations applicable to the final intended use.

Questions to resolve before requesting a bulk quotation

Can one successful positive result justify a bulk order?

It demonstrates a result under one set of conditions. A purchasing decision needs the agreed controls, repeats, validity criteria and assessment of the intended workflow.

Should every strip format use the same signal interpretation?

No. Use the current instructions for the specific model and assay design. Do not transfer test-line interpretation from another lateral flow format without confirmation.

What should we send Due Bio for a pilot discussion?

Send the Cas system, reporter labels, sample matrix, sample preparation approach, intended readout, expected pilot quantity and projected bulk demand. Share the acceptance questions and any existing observations. Avoid sending confidential sequences until the appropriate information-sharing arrangements are agreed.

Contact Due Bio about a CRISPR strip pilot or OEM supply. For published application examples, consult the literature collection and review each study’s actual methods and limitations before transferring it to a new assay.

Product references

TL
Global Agent · Duebio (TiosBio) · 20+ Years in IVD
IVD industry veteran specializing in CRISPR Cas12/Cas13 detection, RAA isothermal amplification, lateral flow assays, microfluidic PCR, TRF immunoassays, and OEM/ODM IVD development for global distributors. Duebio is the international trade brand of TiosBio, a Chinese IVD manufacturer with 20+ years of experience.

Leave a Comment